Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.

OUTCOMES FOLLOWING STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASIS IN OVARIAN CANCER PATIENTS
1Shira Peleg Hasson, 2Nicola Rosenfelder, 3Martin Breuer, 1Angela George, 1Liam Welsh, 1Susana Banerjee, 1Gynae Unit, The Royal Marsden Foundation Trust, London, UK, 1Neuro-Oncology Unit, The Royal Marsden Foundation Trust, London, UK, 1Radiology department, The Royal Marsden Foundation Trust, London, UK

Introduction/Background Brain metastasis (BM), rare in ovarian cancer (OC), is associated with a median overall survival (OS) typically < 1 year. Treatment options include whole brain radiotherapy, stereotactic radiosurgery (SRS) or palliative care. The literature on outcomes following SRS in OC is limited. We report our institutional experience with SRS treatment for BM in an era of targeted therapies.

Methodology OC patients treated with SRS at The Royal Marsden Foundation Trust from 2016–2022 were included. We retrospectively evaluated clinical characteristics, radiation dose and fractionation and survival.

Results 21 OC patients underwent SRS for BM [median age 64 years (range 28–81), 71% FIGO stage III and 29% stage IV at diagnosis, median systemic treatment lines 2 (0–6), 2/21 prior PARP inhibitor]. 18.7% (3/16 patients tested) harboured a BRCA1/2 mutation. Median time from diagnosis to BM was 34 months (range 0–87.9). Neurological symptoms were present in 62% (13/21) of patients, however 19% (4/21) were asymptomatic, identified during screening for clinical trials. At time of BM diagnosis, five patients had BM only (24%) with no evidence of extra-cranial disease. Solitary BM was diagnosed in 62% (8/21) whereas multiple BM (range 2–7) were evident in 62% (13/22). Median treatment dose was 16–24 Gy/1 fraction and 21–24Gy/3 fractions. In 29% (6/21), platinum-based chemotherapy to treat extra-cranial disease was administered within 8 weeks after SRS. Median PFS from BM diagnosis to brain progression was 9.2 months (2.5–50.8), and median PFS from BM to systemic disease progression was 5 months (0–25.3 months). Median OS from SRS treatment was 16 months (1.1–49.7 months). Three patients (14.3%, all BRCA-mutated) received PARPi subsequently to SRS. Among this group mOS was 27 months (9–38).

Conclusion In this retrospective series, overall survival following SRS for BM diagnosis exceeds 1 year. Post SRS, systemic treatment should be considered for selected patients.

DIAgnosis of First Relapse and its Impact on Quality of Life in Patients with Advanced Ovarian Cancer (AGO-ovar 19/II)
1Philipp Hartar, 1Beyhan Ataseven, 1Alexander Burges, 1Alexander Reuss, 2Stefan Koomoss, 1 Jalid Sehoul, 1Björn Lampe, 2Barbara Schmalfeldt, 3Pauline Wimmerber, 4Ralf Witteler, 5Paul Buderath, 5Uwe Henwig, 6Holger Bronger, 6Günter Emons, 7Maximilian Klär, 1Annette Hasenberg, 15Nikolaus de Gregorio, 16 Felix Hilpert, 17Andreas du Bois, 2Sven Mahner, 1Ev, 11Kliniken Essen-Mitte, Essen, Germany; 1University Hospital, LMU Munich, Munich, Germany; 2KKS, Philipp-Universität, Marburg, Germany; 3University Hospital Tübingen, Tübingen, Germany; 4Campus Virchow, Charité, Berlin, Germany; 5Kaiserswerther Diakonie, Düsseldorf, Germany; 6 Universitätsklinik, Hamburg, Hamburg, Germany; 7UKE Hamburg, Hamburg, Germany; 8University Hospital, TU Dresden, Dresden, Germany; 9University Hospital Münster, Münster, Germany; 10University Hospital Essen, Essen, Germany; 11Albertinen Krankenhaus Hamburg, Hamburg, Germany; 12Klinikum rechts der Isar, München, Germany; 13University Hospital Göttingen, Göttingen, Germany; 14University Hospital, Faculty of Medicine, Freiburg, Germany; 15University Hospital Mainz, Mainz, Germany; 16University Hospital Ulm, Ulm, Germany; 17SLK-Kliniken Heilbronn, Heilbronn, Germany; 18Mammazentrum HH am Krankenhaus Jerusalem, Hambur, Germany

Methodology We retrospectively reviewed all of the patients who were diagnosed with advanced epithelial ovarian cancer and who presented with ascites. To maintain the quality of the study, only 92 patients with malignant cells in the ascites were included. Patients with clinically active infection in the time of paracentesis is excluded. If multiple times of paracentesis was done, we used initial result. Curves of DFS and OS were calculated using the Kaplan-Meier method, and univariate and multivariate analyses of various prognostic factors were performed using a Cox proportional hazard regression model.

Results In a univariate analysis, high serum NLR, malignant ascitic NLR were associated with shorter overall survival (p < 0.001, p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), serum NLR (p = 0.007) and malignant ascitic NLR (p = 0.012) were independent predictors of overall survival.

Conclusion Our findings showed that an elevated preoperative NLR in serum and malignant ascites were associated with poor clinical outcome in ovarian cancer patients. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with malignant ascites.

PREOPERATIVE NEUTROPHIL LYMPHOCYTE RATIO IN ASCITES AS A PROGNOSTIC FACTOR IN EPITHELIAL OVARIAN CANCER
1Jung Hyun Park, 1Min Jeong Jeong, 1Chan Joo Kim, 1Yong Seok Lee. 1The catholic university of Korea, Seoul, Korea, Republic of; 2Obstetrics and gynecology, The catholic university of Korea, seoul, Korea, Republic of

Introduction/Background We investigated the clinical impact of NLR as a prognostic factor in malignant ascites in advanced ovarian cancer.